Autopsy report · NCT03400956

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

“Due to a change in the development program, the study was closed prematurely.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 5 months before it stopped.
• 103 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Bayer

Sponsor type

Industry

Conditions

Uterine Fibroids

Interventions

Vilaprisan (BAY1002670); Placebo

Participants

103

Sites

87

Countries

Czechia, Japan, Russia, Ukraine, United States

Trials that died the same way

• Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
  “The study was closed due to the end of funding.” (78% match in meaning)
• An Evaluation of a Novel Food Product in Adults Residing in an Area Endemic for Helminths
  “Due to a business decision to stop the project, the study was terminated early.” (76% match in meaning)
• Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
  “The study was closed after \> 1 year of inactivity.” (74% match in meaning)
• Laryngeal Pacing Study
  “The study was halted early as grant funding was awarded for a new study, which was opened in place of this one.” (73% match in meaning)
• COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
  “The study was closed due to continued enrollment hurdles.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.